Skip to main content

Panbela Therapeutics, Inc.

PBLADelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001029125

Panbela Therapeutics, Inc. was delisted in 2026; its insiders filed their last Form 4 on Nov 19, 2024; no institution reported holding it in 13F filings for Q4 2025; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Panbela Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Panbela Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Panbela Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Soon-Shiong Patrick10% Owner–Nov 19, 20240
Nant Capital, LLC10% Owner–Nov 19, 20240
Horvath SusanV.P. of Finance & CFO17,880Oct 3, 20240
Simpson Jennifer K.President and CEO7,868Oct 3, 20240
Goldman Sachs & Co. LLC10% Owner397,954IndirectNov 13, 20230
Goldman Sachs Group Inc10% Owner397,954IndirectNov 13, 20230
Jacob Jeffrey E.Director0IndirectSep 14, 20230
Mathiesen Jeffrey SDirector–Mar 29, 20230
Fratamico ArthurDirector–Mar 29, 20230
Schemel Donald RobertDirector, 10% Owner482,654IndirectMar 29, 20230
Cullen Michael T.Director, 10% Owner369,576IndirectMar 29, 20230
Donovan DanielDirector–Mar 29, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 19, 2024 (view filing)6:40 PM ETNov 154 daysSoon-Shiong Patrick and 1 other10% OwnerPPurchase+24.7M–––DerivativePrice outlier
Nov 13, 2023 (view filing)7:29 PM ETNov 85 daysGoldman Sachs & Co. LLC and 1 other10% OwnerSSale−72.9K$0.71−$51.7K−15.5%398.0K after
Feb 1, 2023 (view filing)Jan 302 daysSimpson Jennifer K.President and CEOPPurchase+4.44K––+129.8%7.87K after
Feb 1, 2023 (view filing)Jan 302 daysSimpson Jennifer K.President and CEOPPurchase+8.89K$0.00$0–8.89K afterDerivative
Feb 1, 2023 (view filing)Jan 302 daysHorvath SusanV.P. of Finance & CFOPPurchase+4.44K––+33.1%17.9K after
Feb 1, 2023 (view filing)Jan 302 daysHorvath SusanV.P. of Finance & CFOPPurchase+8.89K$0.00$0–8.89K afterDerivative
Oct 6, 2022 (view filing)Oct 42 daysCullen Michael T.Director, 10% OwnerPPurchase+165.0K––+80.7%369.6K after
Oct 6, 2022 (view filing)Oct 42 daysCullen Michael T.Director, 10% OwnerPPurchase+247.0K$0.00$0–247.0K afterDerivative
Oct 6, 2022 (view filing)Oct 42 daysSchemel Donald RobertDirector, 10% OwnerPPurchase+200.0K––+70.8%482.7K after
Oct 6, 2022 (view filing)Oct 42 daysSchemel Donald RobertDirector, 10% OwnerPPurchase+300.0K$0.00$0–300.0K afterDerivative
Oct 6, 2022 (view filing)Oct 42 daysJacob Jeffrey E.DirectorPPurchase+33.0K––+12.6%294.9K after
Oct 6, 2022 (view filing)Oct 42 daysJacob Jeffrey E.DirectorPPurchase+49.5K$0.00$0–49.5K afterDerivative